AB
PHAT icon

Amalgamated Bank’s Phathom Pharmaceuticals PHAT Stock Holding History

Amalgamated Bank’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,248
Closed -$21K – 2500
2025
Q4 		$21K Sell
1,248
-106
-8% -$1.51K ﹤0.01% 2092
2025
Q3 		$16K Hold
1,354
– – ﹤0.01% 2240
2025
Q2 		$13K Hold
1,354
– – ﹤0.01% 2326
2025
Q1 		$8K Buy
1,354
+264
+24% +$1.6K ﹤0.01% 2481
2024
Q4 		$9K Hold
1,090
– – ﹤0.01% 2491
2024
Q3 		$20K Hold
1,090
– – ﹤0.01% 2141
2024
Q2 		$11K Hold
1,090
– – ﹤0.01% 2401
2024
Q1 		$12K Sell
1,090
-1,734
-61% -$14.7K ﹤0.01% 2362
2023
Q4 		$26K Buy
2,824
+249
+10% +$2.15K ﹤0.01% 2535
2023
Q3 		$27K Hold
2,575
– – ﹤0.01% 2516
2023
Q2 		$37K Sell
2,575
-659
-20% -$7.6K ﹤0.01% 2447
2023
Q1 		$23K Sell
3,234
-339
-9% -$2.98K ﹤0.01% 2598
2022
Q4 		$40K Hold
3,573
– – ﹤0.01% 2522
2022
Q3 		$40K Buy
3,573
+55
+2% +$524 ﹤0.01% 2556
2022
Q2 		$30K Buy
3,518
+209
+6% +$2.15K ﹤0.01% 2721
2022
Q1 		$45K Buy
+3,309
New +$53.5K ﹤0.01% 2535

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Amalgamated Bank's PHAT Position: Q1 2026 in Review

Amalgamated Bank sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 1,248 shares — an estimated $21K sold.

Amalgamated Bank first reported a position in PHAT in Q1 2022 and held it in 16 quarters. The position peaked at $45K in Q1 2022. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Amalgamated Bank reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,248 Phathom Pharmaceuticals shares in Q1 2026, an estimated $21K.
  • Amalgamated Bank first reported a position in Phathom Pharmaceuticals in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's Phathom Pharmaceuticals position peaked at $45K in Q1 2022.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.